Lisinopril

Authors

Edgardo Olvera Lopez, The University of Kansas Health System
Mayur Parmar, Nova Southeastern University
Venkata Satish Pendela, Rochester Regional HealthFollow
Jamie M. Terrell, University of LA Monroe

Department

Cardiology

Document Type

Book Chapter

Publication Title

StatPearls [Internet]

Abstract

Lisinopril is classified as an angiotensin-converting enzyme inhibitor and has been available for nearly three decades. Lisinopril has some key features that make it different from enalapril and captopril; 1) it has a long half-life, 2) it is hydrophilic, and 3) it is not broken down by the liver. Lisinopril is a competitive inhibitor of angiotensin-converting enzyme (ACE) and prevents the conversion of angiotensin I to angiotensin II, which is a potent vasoconstrictor. This activity covers lisinopril, including mechanism of action, pharmacology, adverse event profiles, eligible patient populations, monitoring, and highlights the role of the interprofessional team in the management of hypertension with lisinopril.

Publication Date

1-6-2022

Publisher

StatPearls Publishing

PubMed ID

29489196

Recommended Citation

Lopez, E. O., Parmar, M., Pendela, V., & Terrell, J. M. (2022). Lisinopril. StatPearls [Internet] Retrieved from https://scholar.rochesterregional.org/rrhpubs/893